Desvenlafaxine


Concise Prescribing Info
Indications/Uses
Depression.
Dosage/Direction for Use
Adult: PO 50 mg once daily; doses up to 400 mg once daily have been studied but no additional benefit was observed w/ doses >50 mg once daily.
Administration
Extended-release: May be taken with or without food. Take at the same time each day. Swallow whole, do not divide/crush/chew/dissolve tab.
Contraindications
Concurrent use or w/in 14 days of discontinuing MAOIs (e.g. linezolid, IV methylene blue). Initiation of MAOI at least 7 days after discontinuing desvenlafaxine.
Special Precautions
Patient w/ pre-existing HTN or other conditions that may be compromised by increased BP, raised intraocular pressure, personal or family history of mania or hypomania; CV, cerebrovascular or lipid metabolism disorders; seizure disorder. Avoid abrupt withdrawal. Renal and moderate to severe hepatic impairment. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor renal function, BP, lipid panel (e.g. total cholesterol, LDL, triglycerides); signs/symptoms of serotonin syndrome; mental status for depression, suicidal ideation (esp at the beginning of therapy or when doses are increased or decreased); intraocular pressure (in patients w/ baseline elevations or history of glaucoma).
Adverse Reactions
Suicidal thinking/behaviour, HTN, mydriasis, seizure, hyponatraemia, interstitial lung disease and eosinophilic pneumonia; nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, sexual function disorders in males (e.g. anorgasmia, decreased libido, abnormal orgasm, delayed ejaculation, erectile dysfunction, ejaculation disorder, ejaculation failure, sexual dysfunction).
Potentially Fatal: Serotonin syndrome or neuroleptic malignant syndrome-like reactions; haemorrhage.
Drug Interactions
Increased risk of bleeding w/ aspirin or other NSAIDs, warfarin and other anticoagulants.
CIMS Class
ATC Classification
N06AX23 - desvenlafaxine ; Belongs to the class of other antidepressants.
Disclaimer: This information is independently developed by CIMS based on desvenlafaxine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in